SCHEMBL144652

SCHEMBL144652

NC(=O)C1=C(c2ccccc2)c2ccccc2C1O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 4/20 0.47
FGFR2 P21802 4/20 0.47
FGFR4 P22455 4/20 0.47
FGFR3 P22607 4/20 0.47
SRC P12931 3/20 0.47
CRHBP P24387 1/20 0.47
CRHR2 Q13324 1/20 0.47
BCAT2 O15382 2/20 0.46
HTR2B P41595 3/20 0.40
HTR7 P34969 2/20 0.40
LMNA P02545 1/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
HSP90AA1 P07900 1/20 0.37
HSP90AB1 P08238 1/20 0.37
POLB P06746 1/20 0.36
CYP3A4 P08684 1/20 0.36
PARP1 P09874 1/20 0.36
MAPT P10636 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27363609 0.74 ALDH1A1 (0.39) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL28219409 0.73 ALDH1A1 (0.38) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL28219447 0.73 CYP2A6 (0.39) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL1389126 0.72 FGFR1 (0.42) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL30713708 0.70 FGFR1 (0.43) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL1682285 0.70 FGFR1 (0.43) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL7531421 0.67 NPC1 (0.50) FGFR1FGFR2FGFR4FGFR3SRC
Urea SCHEMBL1953346 0.66 BCAT2 (0.67) FGFR1FGFR2FGFR4FGFR3SRC
Carbamic Acid SCHEMBL29581535 0.66 BCAT2 (0.67) FGFR1FGFR2FGFR4FGFR3SRC
Carbamic Acid SCHEMBL27551243 0.66 BCAT2 (0.67) FGFR1FGFR2FGFR4FGFR3SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140221455-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR Verva Pharmaceuticals, Inc. (AU) 2014-08-07 US disclosed
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR VERVA PHARMACEUTICALS PTY LTD (AU) 2012-03-08 US disclosed
US-20050282733-A1 Differentiation modulating agents and uses therefor VERVA PHARMACEUTICALS PTY LTD (AU) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR FGF1, FABP4, FGF2 FGFR1 5/4885FGFR2 6/4885FGFR4 15/4885
US-20050282733-A1 Differentiation modulating agents and uses therefor FGF1, FABP4, FGF2 FGFR1 5/4885FGFR2 6/4885FGFR4 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.